Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

– 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. – Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: […]